Top

Published in:

01-10-2008 | Preclinical study

Tumor-derived CCL5 does not contribute to breast cancer progression

Authors: Mevan M. Jayasinghe, Jacqueline M. Golden, Priyanka Nair, Cara M. O’Donnell, Michael T. Werner, Robert A. Kurt

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Abstract

Besides functioning as a chemotactic factor, CCL5 has been associated with progression of disease in women with breast cancer, immune modulation and metastasis. Here we asked whether CCL5 produced by tumor cells contributed to growth or metastasis of breast cancer. For this purpose, we used two murine mammary carcinomas, the 4T1 tumor which is metastatic and constitutively expresses CCL5, and the 168 tumor which is not metastatic and does not constitutively express CCL5. RNA interference was used to inhibit CCL5 expression from the 4T1 tumor, and a CCL5 transgene was used to express CCL5 by the 168 tumor. Six different clones of 4T1 that exhibited stable reduction in CCL5 expression, and three different clones of 168 that exhibited stable CCL5 expression were compared to the parental tumors and vector transfected controls. Significantly, in both models, tumor-derived CCL5 expression did not correlate with MHC expression, growth rate, or metastatic ability of the tumors. These results show that tumor-derived CCL5 expression alone does not make a significant contribution to breast cancer progression.

Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM (1988) A human T cell-specific molecule is a member of a new gene family. J Immunol 141:1018–1025PubMed

Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347:669–671PubMedCrossRef

Roth SJ, Carr MW, Springer TA (1995) C–C chemokines, but not the C–X–C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes. Eur J Immunol 25:3482–3488PubMedCrossRef

de la Rosa G, Longo N, Rodriguez-Fernandez JL, Puig-Kroger A, Pineda A, Corbi AL, Sanchez-Mateos P (2003) Migration of human blood dendritic cells across endothelial cell monolayers: adhesion molecules and chemokines involved in subset-specific transmigration. J Leukoc Biol 73:639–649CrossRef

Taub DD, Sayers TJ, Carter CR, Ortaldo JR (1995) Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 155:3877–3888PubMed

Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM (1992) Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587–592PubMedCrossRef

Conti P, Pang X, Boucher W, Letourneau R, Reale M, Barbacane RC, Thibault J, Theoharides TC (1997) RANTES is a pro-inflammatory chemokine and chemoattracts basophil cells to extravascular sites. J Pathol 183:352–358PubMedCrossRef

Appay V, Dunbar PR, Cerundolo V, McMichael A, Czaplewski L, Rowland-Jones S (2000) RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. Int Immunol 12:1173–1182PubMedCrossRef

Cridge TJ, Horowitz KM, Marinucci MN, Rose KM, Wells M, Werner MT, Kurt RA (2006) Functional and molecular alterations in T cells induced by CCL5. Immunol Invest 35:115–132PubMedCrossRef

10.

Bandeira-Melo C, Phoofolo M, Weller PF (2001) Extranuclear lipid bodies, elicited by CCR3-mediated signaling pathways, are the sites of chemokine-enhanced leukotriene C4 production in eosinophils and basophils. J Biol Chem 276:22779–22787PubMedCrossRef

11.

Locati M, Deuschle U, Massardi ML, Martinez FO, Sironi M, Sozzani S, Bartfai T, Mantovani A (2002) Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol 168:3557–3562PubMed

12.

Yao TC, Kuo ML, See LC, Ou LS, Lee WI, Chan CK, Huang JL (2006) RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study. Arthritis Rheum 54:2585–2593PubMedCrossRef

13.

Stanczyk J, Kowalski ML, Grzegorczyk J, Szkudlinska B, Jarzebska M, Marciniak M, Synder M (2005) RANTES and chemotactic activity in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Mediators Inflamm 2005:343–348PubMedCrossRef

14.

McCormack G, Moriarty D, O’Donoghue DP, McCormick PA, Sheahan K, Baird AW (2001) Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 50:491–495PubMedCrossRef

15.

Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38–52PubMedCrossRef

16.

Mrowietz U, Schwenk U, Maune S, Bartels J, Kupper M, Fichtner I, Schroder JM, Schadendorf D (1999) The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 79:1025–1031PubMedCrossRef

17.

Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG (2002) RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 8:3803–3812PubMed

18.

Vaday GG, Peehl DM, Kadam PA, Lawrence DM (2006) Expression of CCL5 (RANTES) and CCR5 in prostate cancer. The Prostate 66:124–134PubMedCrossRef

19.

Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A, Balzano G, Di Carlo V, Allavena P, Piemonti L (2004) A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch 445:236–247PubMedCrossRef

20.

Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A (1999) Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59:4681–4687PubMed

21.

Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7:285–289PubMed

22.

Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I, Ben-Baruch A (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12:4474–4480 PubMedCrossRef

23.

Robinson SC, Scott KA, Balkwill FR (2002) Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 32:404–412PubMedCrossRef

24.

Kurt RA, Baher A, Wisner KP, Tackitt S, Urba WJ (2001) Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol 207:81–88 PubMedCrossRef

25.

Kurt RA, Bauck M, Harma S, Adler E, Vitiello P, Wisner KP, Tackitt S, Urba WJ (2003) Altered chemokine receptor sensitivity in FVBN202 rat neu transgenic mice. Breast Cancer Res Treat 77:225–232PubMedCrossRef

26.

Aslakson CL, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399–1405PubMed

27.

Miller FR, Miller BE, Heppner GH (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Met 3:22–31

28.

Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15:188–200PubMedCrossRef

29.

Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553PubMedCrossRef

30.

Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16:948–958PubMedCrossRef

31.

Eissa SAL, Zaki SA, El-Maghraby SM, Kadry DY (2005) Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst 17:51–55PubMed

32.

Ali S, Kaur J, Patel KD (2000) Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol 157:313–321PubMed

33.

Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62:1093–1102PubMed

34.

Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AEI, Balkwill FR (2003) A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63:8360–8365PubMed

35.

Adler EP, Lemken CA, Katchen NS, Kurt RA (2003) A dual role for tumor-derived RANTES (CCL5). Immunol Lett 90:187–194PubMedCrossRef

36.

Stormes KA, Lemken CA, Lepre JV, Marinucci MN, Kurt RA (2005) Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat 89:209–212 PubMedCrossRef

37.

Azenshtein E, Meshel T, Shina S, Barak N, Keydar I, Ben-Baruch A (2005) The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett 217:73–86 PubMedCrossRef

38.

Shahrara S, Park CC, Temkin V, Jarvis JW, Volin MV, Pope RM (2006) RANTES modulates TLR4-induced cytokine secretion in human peripheral blood monocytes. J Immunol 177:5077–5087PubMed

39.

Appay V, Rowland-Jones SL (2001) RANTES: a versatile and controversial chemokine. Trends Immunol 22:83–87PubMedCrossRef

40.

Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A (1983) Regulation of the macrophage content of neoplasms by chemoattractants. Science 220:210–212 PubMedCrossRef

41.

Bottazzi B, Colotta F, Sica A, Nobili N, Mantovani A (1990) A chemoattractant expressed in human sarcoma cells (tumor-derived chemotactic factor, TDCF) is identical to monocyte chemoattractant protein-1/monocyte chemotactic and activating factor (MCP-1/MCAF). Int J Cancer 45:795–797PubMedCrossRef

42.

Vitiello PF, Shainheit MG, Allison EM, Adler EP, Kurt RA (2004) Impact of tumor-derived CCL2 on T cell effector function. Immunol Lett 91:239–245PubMedCrossRef

43.

Brault MS, Kurt RA (2005) Impact of tumor-derived CCL2 on macrophage effector function. J Biomed Biotech 1:37–43CrossRef

44.

Westby M, van der Ryst E (2005) CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 16:339–354PubMed

45.

Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y (2005) TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 49:4584–4591PubMedCrossRef

Title: Tumor-derived CCL5 does not contribute to breast cancer progression
Authors: Mevan M. Jayasinghe
Jacqueline M. Golden
Priyanka Nair
Cara M. O’Donnell
Michael T. Werner
Robert A. Kurt
Publication date: 01-10-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9802-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Differences in breast cancer biological characteristics between ethnic groups in New Zealand

A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk

BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer

NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells

JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer

Genetic polymorphisms of XRCC1 (codon 399) and susceptibility to breast cancer in Iranian women, a case–control study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer